The Activity of Matrix Metalloproteinases (MMP-2, MMP-9) and Their Tissue Inhibitors (TIMP-1, TIMP-3) in the Cerebral Cortex and Hippocampus in Experimental Acanthamoebiasis

Natalia Łanocha-Arendarczyk 1, Irena Baranowska-Bosiacka 2, Izabela Gutowska 3, Agnieszka Kolas-Wołosiuk 4, Karolina Kot 1, Aleksandra Łanocha 5, Emilia Metryka 2, Barbara Wiszniewska 4, Dariusz Chlubek 2 and Danuta Kosik-Bogacka 1,*

1 Department of Biology and Medical Parasitology, Pomeranian Medical University in Szczecin, 70-204 Szczecin, Poland; nlanocha@pum.edu.pl (N.L.-A.); kotkarolina17@gmail.com (K.K.)
2 Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, 70-204 Szczecin, Poland; ika@pum.edu.pl (I.B.-B.); emilia_metryka@o2.pl (E.M.);
dchlubek@pum.edu.pl (D.C.)
3 Department of Biochemistry and Human Nutrition, Pomeranian Medical University in Szczecin, 70-204 Szczecin, Poland; izagut@poczta.onet.pl
4 Department of Histology and Embryology, Pomeranian Medical University in Szczecin, 70-204 Szczecin, Poland; Agnieszka.Kolas@pum.edu.pl (A.K.-W.); kzhe@pum.edu.pl (B.W.)
5 Department of Haematology and Transplantology, Pomeranian Medical University in Szczecin, 70-204 Szczecin, Poland; aleksandra.lanocha@pum.edu.pl

* Correspondence: kodan@pum.edu.pl; Tel.: +48-91-466-1672

Received: 27 November 2018; Accepted: 14 December 2018; Published: 19 December 2018

Abstract: The pathological process occurring within the central nervous system (CNS) as a result of the infection by Acanthamoeba spp. is not fully understood. Therefore, the aim of this study was to determine whether Acanthamoeba spp. may affect the levels of matrix metalloproteinases (MMP-2,-9), their tissue inhibitors (TIMP-1,-3) and MMP-9/TIMP-1, MMP-2/TIMP-3 ratios in the cerebral cortex and hippocampus, in relation to the host’s immunological status. Our results showed that Acanthamoeba spp. infection can change the levels of MMP and TIMP in the CNS and may be amenable targets for limiting amoebic encephalitis. The increase in the activity of matrix metalloproteinases during acanthamoebiasis may be primarily the result of inflammation process, probably an increased activity of proteolytic processes, but also (to a lesser extent) a defense mechanism preventing the processes of neurodegeneration.

Keywords: matrix metalloproteinases (MMP); tissue inhibitor of metalloproteinases (TIMP); Acanthamoeba spp.; cerebral cortex; hippocampus

1. Introduction

Acanthamoeba spp. can penetrate into the human central nervous system (CNS) and cause granulomatous amoebic encephalitis (GAE), a chronic infection often confused with bacterial or viral invasions, with non-specific symptoms and mortality exceeding 95% [1–3]. Trophozoites of these amoebae usually reach the CNS through the bloodstream from the site of primary pathology, such as the cornea of the eye, skin (ulceration), and the respiratory system (lungs) [4–6]. After the blood–brain barrier (BBB) has been compromised by the parasites, neutrophils and macrophages release mediators of inflammatory reactions as well as reactive oxygen species and nitric oxide [7]. The inflammation results in the production of cytokines, including tumor necrosis factor (TNF) and
interleukins (IL-1, IL-6), leading to a synergistic effect on endothelial cells, inducing the synthesis of adhesive particles [2,8,9]. The pathological process occurring within the CNS as a result of the infection by Acanthamoeba spp. is not fully understood. In vitro studies show that increased permeability of the BBB is enhanced by extracellular serine proteases which degrade the tight junction proteins [2]. One of the factors responsible for the breaching of the blood–brain barrier, the degeneration of myelin proteins, as well as those acting on cytokines and chemokines, are extracellular matrix metalloproteinases (MMP) [10]. Metalloproteinases-2 (MMP-2) and -9 (MMP-9) regulate growth, proliferation, cell apoptosis, degrade type IV collagen, and have the potential to damage the basement membrane [11,12]. Their role has been demonstrated in inflammatory and infectious diseases of the nervous system in experiments on laboratory animals, e.g., in bacterial meningitis. The induction of their activity allows the lymphocytes to migrate through the compromised BBB and contribute to nerve tissue damage [13]. An increased activity of MMP-2 and MMP-9 has been observed in infections of tropical protozoa to the CNS, e.g., Plasmodium falciparum and Trypanosoma brucei gambiense [14]. In addition, the expression of some MMP increases in opportunistic infections, including Toxoplasma gondii, Leishmania spp. and Trypanosoma cruzi in immunocompromised hosts [15]. Lam et al. [16] suggested that MMP plays a critical role in the in vivo infection of the CNS, and that amenable targets may exist for limiting Naegleria fowleri brain infection. The cellular mechanism underlying Acanthamoeba spp. brain infection in relation to MMP and tissue inhibitors of metalloproteinases (TIMP) in experimental acanthamoebiasis in relation to the host immunological status is largely unknown. TIMP provide the necessary balance to prevent excessive degradation of extracellular matrix molecules. Disturbances in the balance between the metalloproteinases and their tissue inhibitors (MMP/TIMP) are most often associated with progressive pathological changes in the nervous system [17]. A strong correlation observed between MMP and TIMP may suggest a possible role of immune mediators in the immunopathogenesis of viral brain infections [18]. The role of MMP-2 and MMP-9 and their tissue inhibitors TIMP-1 and TIMP-3 in extracellular proteolysis is directly connected with the formation and maintenance of a normal perineuronal network structure surrounding neurons, which is important for the creation of new synaptic connections. As no studies to date have addressed the implications of the role of MMP and TIMP in Acanthamoeba spp. brain infections in immunocompetent or immunosuppressed hosts, the purpose of this study was to determine whether Acanthamoeba spp. may affect the levels of MMP (-2,-9), their tissue inhibitors TIMP (-1,-3) and MMP-9/TIMP-1, MMP-2/TIMP-3 ratios in the cerebral cortex and hippocampus, in relation to the host’s immunological status.

2. Results

2.1. MMP-2 in the Cerebral Cortex and Hippocampus during Acanthamoebiasis

The highest levels of MMP-2 in Acanthamoeba spp. infected immunocompetent mice were found in the cerebral cortex at 8 days post Acanthamoeba spp. infection (dpi) (0.22 ng/mg protein) and the lowest in the hippocampus in control immunocompetent mice at 24 dpi (0.07 ng/mg protein). MMP-2 in the cerebral cortex of the immunosuppressed had a significantly higher level compared to immunocompetent Acanthamoeba spp. infected mice at 16 dpi (Figure 1).
Figure 1. Matrix metalloproteinases-2 (MMP-2) level (ng/mg protein) in the cerebral cortex and hippocampus in control and infected groups at 8, 16 and 24 days post *Acanthamoeba* spp. infection (dpi). Data represent means ± SD for 6 independent experiments. C, immunocompetent uninfected control group mice; CS, immunosuppressed uninfected control group mice; A, immunocompetent *Acanthamoeba* spp. infected mice; AS, immunosuppressed *Acanthamoeba* spp. infected mice; *p* ≤ 0.05 for the significance of difference (Mann–Whitney U test).

2.2. MMP-9 in the Cerebral Cortex and Hippocampus during Acanthamoebiasis

The highest level of MMP-9 was demonstrated in the hippocampus of *Acanthamoeba* spp. infected immunocompetent mice at 8 dpi (651.67 pg/mg protein) and the lowest in the cerebral cortex of control immunocompetent mice at 8 dpi (137.17 pg/mg protein). In the *Acanthamoeba* spp. infected immunocompetent mice the level of MMP-9 protein in the cerebral cortex was significantly higher than in the control group at 8 dpi (by 72%, *p* = 0.02). In the cerebral cortex of *Acanthamoeba* spp. infected mice we found downregulation of MMP-9 levels at 16 dpi, but the observed differences were not statistically significant (Figure 2). We noted a significantly lower MMP-9 level in the hippocampus at 24 dpi in the immunosuppressed *Acanthamoeba* spp. infected mice (AS group) compared to the immunosuppressed uninfected mice (CS group) (*p* = 0.04). Moreover, MMP-9 level in the *Acanthamoeba* spp. infected immunocompetent mice differed significantly between the cerebral cortex and hippocampus at 16 dpi (*p* = 0.03). There were no significant differences in MMP-9 levels in the studied brain structures between immunocompetent and immunosuppressed *Acanthamoeba* spp. infected mice.
There was significant difference in TIMP-1 level in the cerebral cortex between the immunocompetent and immunosuppressed groups at 8 dpi (by 73.2%, \( p = 0.04 \) at 8 dpi and (by 62.7%, \( p = 0.02 \) at 16 dpi (Figure 3)).

2.3. TIMP-1 in the Cerebral Cortex and Hippocampus during Acanthamoebiasis

In the *Acanthamoeba* spp. infected immunocompetent mice the level of TIMP-1 protein in the cerebral cortex was significantly higher than in the control group at 8 dpi (by 80.3%, \( p = 0.04 \)). There was significant difference in TIMP-1 level in the cerebral cortex between the immunocompetent and immunosuppressed *Acanthamoeba* spp. infected mice at 8 dpi (by 61%, \( p = 0.01 \)). We found significant downregulation of TIMP-1 protein in the hippocampus of the *Acanthamoeba* spp. infected immunocompetent mice compared to the immunosuppressed infected group (by 62.7%, \( p = 0.05 \)) at 8 dpi. There were significant differences in TIMP-1 levels in the cerebral cortex and hippocampus between the immunocompetent and immunosuppressed *Acanthamoeba* spp. infected mice (by 41.6%, \( p = 0.04 \)) at 8 dpi and (by 73.2%, \( p = 0.02 \)) at 16 dpi (Figure 3).
Data represent means ± SD for 6 independent experiments. C, immunocompetent uninfected control group mice; CS, immunosuppressed uninfected control group mice; A, immunocompetent *Acanthamoeba* spp. infected mice; AS, immunosuppressed *Acanthamoeba* spp. infected mice; *p* ≤ 0.05 for the significance of difference (Mann–Whitney U test).

2.4. TIMP-3 in the Cerebral Cortex and Hippocampus during Acanthamoebiasis

The level of TIMP-3 in the cerebral cortex was significantly higher in the immunocompetent than immunosuppressed *Acanthamoeba* spp. infected mice at 8 dpi (by 81.7%, *p* = 0.008) (Figure 4). We observed downregulation in the hippocampus of immunosuppressed *Acanthamoeba* spp. infected mice compared to the immunosuppressed control group at 16 dpi (by 69%, *p* = 0.04). TIMP-3 level in *Acanthamoeba* spp. infected immunosuppressed mice in the cerebral cortex did not exceed 0.2 ng/mg. There were no significant differences in TIMP-3 level between the cerebral cortex and hippocampus.

![Figure 4](image-url)

**Figure 4.** Tissue inhibitors of metalloproteinase-3 (TIMP-3) level (ng/mg) in the cerebral cortex and hippocampus in control and infected groups at 8, 16 and 24 days post *Acanthamoeba* spp. infection (dpi). Data represent means ± SD for 6 independent experiments. C, immunocompetent uninfected control group mice; CS, immunosuppressed uninfected control group mice; A, immunocompetent *Acanthamoeba* spp. infected mice; AS, immunosuppressed *Acanthamoeba* spp. infected mice; *p* ≤ 0.05 for the significance of difference (Mann–Whitney U test).

2.5. MMP-9/TIMP-1 and MMP-2/TIMP-3 Ratios in the Brain Structures

The MMP-9/TIMP-1 ratio was greater in the hippocampus of the immunosuppressed *Acanthamoeba* spp. infected mice (AS group) than of the control at the beginning of infection. A similar trend was noted in *Acanthamoeba* spp. infected immunosuppressed mice in MMP-2/TIMP-3 ratio at 8 dpi, but the difference was not significant.

2.6. Immunohistochemistry

2.6.1. MMP-2

In neocortex MMP-2 immunoeexpression (Figure 5a) was mainly detected at the beginning of the experiment (8 dpi) in all studied group of mice. In infected animals (Figure 5a(A,D)) it was more prominent than in control (Figure 5a(G,J)). During the following day of infection/suppression, in the IHC analysis the reactivity was almost absent (Figure 5a(B,C, E,F, H,J, K,L)). In the hippocampus, mainly neurons of granular cell layer (GCL) of dentate gyrus (Figure 5b) and pyramidal cell layer
(PyrCL) of cornu ammonis (Figure 5c) exhibited immunoexpression of detected proteins. Therefore, these cells were taken into consideration in the discussion of MMP-2 immunolocalization in the hippocampus. In dentate gyrus, similarly MMP-2 occurred mainly at the beginning of experiment (8 dpi) in all studied group of mice. However, it was more evident and spread across the entire GCL in immunocompetent mice (Figure 5b(A,G); red asterisks); immunosuppressed animals showed occasionally visible MMP-2-positive neurons in the granular cell layer (Figure 5b(D,J)). Generally, at 16 dpi and 24 dpi of all group immunoreactivity was weak and rare, almost no detectible (Figure 5b(B,C,E,F,H,I,K,L)), such as in neocortex. Similarly to neocortex and dentate gyrus, in cornu ammonis MMP-2 (Figure 5c(A–L)) could be observed mainly at the beginning of experiment (8 dpi) in the studied groups of mice (A, AS and C). Generally, at 16 and 24 dpi immunoreactivity in all groups was weak and rare, almost undetectable (Figure 5c(B,C,F,I,K,L)).

(a) 

(b) 

Figure 5. Cont.
The results of the immunohistochemical reactions (IHC) showed that in the neocortex (Figure 6a), dentate gyrus (Figure 6b) and cornu ammonis (Figure 6c) of mice from control immunocompetent group of mice (C; Figure 6a–c(G–l)) the intensity of immunexpression of MMP-9 was different from MMP-9 expression in immunosuppressed uninfected control group (CS, Figure 6a–c(J–L)), immunosuppressed infected with *Acanthamoeba* spp. (AS, Figure 6a–c(D–F)) and immunocompetent infected mice (A, Figure 6a–c(A–C)). The observed changes depended on the duration of infection or immunosuppressant treatment. The results of IHC reactions in different part of murine brains (Figure 6a–c) reflected the results of ELISA analysis and also showed the fluctuating intensity tensions of MMP-9 immunexpression. In neocortex (Figure 6a) MMP-9 immunexpression was more pronounced in animals infected by *Acanthamoeba* (Figure 6a(A–F)) than in controls (Figure 6a(G–L)) especially at the initial (Figure 6a(A,D)) and final/decay (Figure 6a(C–F)) stages of infection.

### Table: Immunohistochemical Reactions

| 8 dpi | 16 dpi | 24 dpi |
|-------|--------|--------|
| A     | AS     | C      | CS     |
| B     | E      | F      |         |
| C     | F      |         |         |

**Figure 5.** (a) Representative microphotography showing immunoexpression (brown color) of matrix metalloproteinases-2 (MMP-2) in the neocortex of mice from control group (a, G–I), immunosuppressed uninfected control group (a, J–L), immunocompetent infected by *Acanthamoeba* spp. (A, A–C) and immunosuppressed *Acanthamoeba* spp. infected group (a, D–F) in 8, 16, and 24 day post infection (dpi). White arrows show immunexpression of MMP-2 in the neurons of cerebral cortex at the beginning of experiment (5a, A,D,G,J); in following days of experiment (5a, B,E,H,I,K,L) the MMP-2 in IHC procedure is under detection level. (b) Representative microphotography showing immunexpression (brown color) of MMP-2 in neurons of granular cell layer (GCL) of the gyrus dentatus of mice from control group (b, G–I), immunosuppressed uninfected control group (b, J–L), immunocompetent infected by *Acanthamoeba* spp. (b, A–C) and immunosuppressed *Acanthamoeba* spp. infected group (b, D–F) in 8, 16, and 24 dpi. White arrows show immunexpression of MMP-2 in the neurons of that region of hippocampus. Red asterisks, in some cases (b, A,G), shows tendency to immunolocalization of MMP-2 over the whole thickness of GCL. In following days of experiment (b, C,E,F,H,I,K,L) the MMP-2 in IHC procedure is under detection level. (c) Representative microphotography showing immunexpression (brown color) of MMP-2 in the neurons of pyramidal cell layer (PyrCL) of cornu ammonis of mice from control group (c, G–I), immunosuppressed uninfected control group (c, J–L), immunocompetent infected by *Acanthamoeba* spp. (c, A–C) and immunosuppressed *Acanthamoeba* spp. infected group (c, D–F) in 8, 16, and 24 dpi. White arrows show immunexpression of MMP-2 in the neurons of hippocampus mainly at the beginning of experiment (c, A,D,G); in following days of experiment (c, B,C,F,H,I,J,L) the MMP-2 in IHC procedure is under detection level. Objective magnification a–c: ×100. Scale bar = 20 μm.
However, in the CS group the intensity of MMP-9 immunoreactivity was also high at 24 dpi (Figure 6a(L)). Immunoexpression of MMP-9 in dentate gyrus (Figure 6b) of immunosuppressed infected (Figure 6b(D–F)) and control mice (Figure 6b(G–I)) was higher than in immunocompetent infected (Figure 6b(A–C)) or immunosuppressed non-infected mice (Figure 6b(J–L)). Generally in the hippocampus of mice with increased immunoreactivity to MMP-9, we observed a tendency to increased immunoexpression of the studied marker, especially in the basal region of GCL (Figure 6b, white asterisk). The highest MMP9-immunoreactivity is noticeable in pyramidal cell layer (PyrCL) of cornu ammonis of infected mice in the course of all infection (Figure 6c(A–C)) and also high in 8 postinfection day of immunosuppressed mice (Figure 6c, D); control groups of mice the immunosuppressant treatment result in rise of MMP9 immunoexpression (Figure 6c(J–L)) in comparison to control, untreated animals (Figure 6c(G–I)).

(a)

(b)

Figure 6. Cont.
TIMP-1 expression in dentate gyrus of hippocampus mainly in the period of the experiment. The expression of TIMP-1 in AS (Figure 7b(D–F)) and in C (Figure 7b(G–I)) groups of mice was rather low. In cornu ammonis, the nerve cells immunoreactivity for TIMP-1 in immunocompetent infected mice (Figure 7c, A–C) and immunosuppressed infected mice (Figure 7c(J–L)) the TIMP-1 immunoexpression was a little bit higher during the following days of experiment (16 and 24 dpi). Similarly, in immunocompetent control (Figure 7a(G–I)) and immunosuppressed control groups (Figure 7a(J,L)) the TIMP-1 immunoexpression was lower at 8 dpi (Figure 7a(D)).

**Figure 6.** (a) Representative microphotography showing immunoexpression (brown color) of MMP-9 in the neocortex of mice from control group (a, G–I), immunosuppressed uninfected control group (a, J–L), immunocompetent infected by *Acanthamoeba* spp. (a, A–C) and immunosuppressed *Acanthamoeba* spp. infected group (a, D–F) in 8, 16 and 24 day post infection (dpi). White arrows show immunoexpression of MMP9 in the neurons of cerebral cortex. (b) Representative microphotography showing immunoexpression (brown color) of MMP-9 in the neurons of granular cell layer (GCL) of gyrus dentatus of mice from control group (b, G–I), immunosuppressed uninfected control group (b, J–L), immunocompetent infected by *Acanthamoeba* spp. (b, A–C) and immunosuppressed *Acanthamoeba* spp. infected group (b, D–F) in 8, 16, and 24 dpi. White arrows show immunoexpression of MMP-9 in the neurons of that region of hippocampus. White asterisk, in some cases, shows tendency to immunolocalization of MMP-9 in basal region of GCL. c) Representative microphotography showing immunoexpression (brown color) of MMP-9 in neurons of pyramidal cell layer (PyrCL) of cornu ammonis of mice from control group (c, G–I), immunosuppressed uninfected control group (c, J–L), immunocompetent infected by *Acanthamoeba* spp. (c, A–C) and immunosuppressed *Acanthamoeba* spp. infected group (c, D–F) in 8, 16, and 24 dpi. White arrows show immunoexpression of MMP-9 in neurons of that region of hippocampus. Objective magnification a–c: ×100. Scale bar = 20 μm.

### 2.6.3. TIMP-1

TIMP-1 immunoexpression in neocortex (Figure 7a) was more intense in mice infected with *Acanthamoeba* spp. (Figure 7a(A–F)) than in uninfected animals (Figure 7a(G–L)). In the infected group immunoreactivity was most intense at 8 dpi (Figure 7a(A)) then at the following days of the experiment (Figure 7a(B,C)), and opposite to immunosuppressed infected mice, was lower at 8 dpi (Figure 7a(D)), higher at 16 and 24 dpi (Figure 7a(E–F)). Similarly, in immunocompetent control (Figure 7a(G–I)) and immunosuppressed control groups (Figure 7a(J,L)) the TIMP-1 immunoexpression was a little bit higher during the following days of experiment (16 and 24 dpi). Immunohistochemical procedure showed TIMP-1 expression in dentate gyrus of hippocampus mainly in the *Acanthamoeba* spp. infected mice (Figure 7b(A–C)) and in the immunosuppressed uninfected animals (Figure 7b(J–L)) over the entire period of the experiment. The expression of TIMP-1 in AS (Figure 7b(D–F)) and in C (Figure 7b(G–I)) groups of mice was rather low. In cornu ammonis, the nerve cells immunoreactivity for TIMP-1 (Figure 7c) was much higher in immunocompetent infected mice (Figure 7c(A–C)) than in control animals (Figure 7c(G–I)); the immunosuppressive treatment caused abolition of the immunoreactivity in both groups of mice (Figure 7c(D–F,J–L)).
immunesuppressive treatment caused abolition of the immunoreactivity in both groups of mice (Figure 7c, D–F, J–L).

(a)

(b)

Figure 7. Cont.
2.6.4. TIMP-3

The lowest level of the TIMP-3 (Figure 8a) was observed in the neocortex of control mice (Figure 8a(G–I)); the Acanthamoeba spp. infection (Figure 8a(A–C)) and (Figure 8a(D–F))/or (Figure 8a(I–L)) immunosuppressive treatment resulted in enhancement/intensification of the immunoreactivity, regardless of the duration of the experiment. In the dentate gyrus, the highest expression of TIMP-3 (Figure 8b) was visible in the infected animal at the beginning of infection (Figure 8b(A)) and then decreased (Figure 8b(B,C)); in the control group the expression of TIMP-3 was similar during the entire period of experiment (Figure 8b(G–I)), immunosuppression decreased TIMP-3 expression (Figure 8b(D–F,J–L)) in comparison to controls, i.e., immunocompetent Acanthamoeba spp. infected (A group) and immunocompetent uninfected (C group) mice. In the cornu ammonis of the hippocampus, the intensity of immunooexpression of TIMP-3 (Figure 8c(A–L)) was very similar to that observed in dentate gyrus (Figure 8b(A–L))–the highest in the immunocompetent infected mice (Figure 8c(A–C)), high in control (Figure 8c(G–I)) and the lowest in immunosuppressed infected/uninfected mice (Figure 8c(D–F,J–L)).
Figure 8. Cont.
Infections caused by Acanthamoeba secreted MMP that play a role in the brain infection [16]. Immunosuppression appears to be a factor in the infection of Naegleria fowleri, which invade the host organism by ingesting tissue and producing metalloproteinase enzymes [19]. Similarly, MMP activity is crucial for the migration of inflammatory cells and parasites as well as BBB integrity. The imbalance between MMP and endogenous MMP inhibitors, mostly in favor of active proteolysis [14]. The inflammation induced by parasites may be associated with the influx of leukocytes, among others to the brain, resulting in immunopathology and collateral tissue damage [15].

3. Discussion

Some opportunistic parasitic invasions are accompanied by the imbalance between MMP and endogenous MMP inhibitors, mostly in favor of active proteolysis [14]. The inflammation induced by parasites may be associated with the influx of leukocytes, among others to the brain, resulting in immunopathology and collateral tissue damage [15]. In the case of parasitic cerebral infections, MMP activity is crucial for the migration of inflammatory cells and parasites as well as BBB integrity disorders [18]. It is noted that Acanthamoeba spp. and Balamuthia mandrillaris, GAE etiologic agents, invade the host organism by ingesting tissue and producing metalloproteinase enzymes [19]. Similarly, Naegleria fowleri trophozoites, isolated from a fatal case of primary amebic meningoencephalitis, secreted MMP that play a role in the brain infection [16]. Immunosuppression appears to be a factor in brain infections caused by Acanthamoeba spp., which are predominantly lethal and often diagnosed postmortem [20].
MMP-2 and MMP-9 play a role in neurological disorders. MMP-2 is constitutively expressed by several cell types including brain tissue, and participates in BBB damage and immunological pathogenesis [12]. In addition, it plays a role in the growth, infiltration and formation of cancer metastases [21]. Similar to monocytes, T-cells, astrocytes, microglia, and macrophages, neutrophils flow to damaged tissues and release large amounts of MMP-9 from their granules [14,22].

This study demonstrated that in the Acanthamoeba spp. infected immunocompetent mice the level of MMP-9 protein in the cerebral cortex was significantly higher than in the control group at the beginning of infection. Moreover, we noted that MMP-9 level in the amoeba infected immunocompetent hosts was significantly different between brain structures at 16 dpi. Some researchers found that MMP-2 and MMP-9 are expressed in the hippocampus, striatum, diencephalon, mesencephalon, frontal cortex, and cerebellum of rats, with the activity of both proteins being the highest within the hippocampus, the brain part responsible for the conversion of short-term to long-term memory via long-term potentiation (LTP) [23]. Our study confirmed the variability of MMP concentrations within brain structures in acanthamoebiasis in both immunocompetent and immunocompromised hosts.

We also found a significant upregulation of MMP-2 levels in the cerebral cortex of Acanthamoeba spp. infected immunosuppressed mice compared to amoeba–infected immunocompetent hosts, but only at 16 dpi. In some studies, the increasing levels of MMP-2 and MMP-9 correlated with the presence of parasites and leukocytes in the cerebrospinal fluid (CSF) of Trypanosoma brucei gambiense infected patients with the final stage of African sleeping sickness [14]. Jacintho et al. [24] noted increasing levels of MMP-9 in dogs with visceral leishmaniasis. Also patients with Chagas heart disease complicated by heart failure had higher serum levels of MMP-9 [25]. In experimental Trypanosoma cruzi infection, Gutierrez et al. [26] showed that the inhibition of MMP-2 and MMP-9 increased inflammation.

The secretion of MMP is initiated by various factors, e.g., platelet-derived growth factor (PDGF), interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-α) and phagocytosis. The secretion is inhibited by transforming growth factor β (TGF-β) and glucocorticoids. During Toxoplasma gondii-induced immune response and inflammation, IL-1, IL-23, TNF-α, and cyclooxygenase-2 (COX-2) stimulated the production of MMP in the brain [27].

In this study we found that at 24 dpi, the level of MMP-9 was significantly lower in the hippocampus of the Acanthamoeba spp. infected mice with reduced immunity, induced by methylprednisolone (drug used to suppress the immune system and decrease inflammation). Corticosteroids have been shown to suppress the expression of MMP-9 in CSF during acute CNS inflammation [28]. Synthetic MMP inhibitors (including steroids) may inhibit the production of prostaglandin 2 (PGE_2) and cyclic AMP (cAMP) that also mediate the production of MMP. Green et al. [29] found that dexamethasone decreased the cerebrospinal fluid MMP-9 concentrations early in the treatment and this may represent one mechanism by which corticosteroids improve outcomes in meningitis.

MMPs participate in neurodegeneration, with recent research also indicating their involvement in the development of nervous system and neuroplastic processes activated as a result of nerve tissue damage [12]. Changes in the concentration of MMP-2 and MMP-9 are independent of each other, and both of these enzymes may play different roles in damage and regeneration of nervous system tissue. Increased MMP-2 synthesis in the brains of mice infected with Acanthamoeba spp. may be associated with regenerative processes that occur due to the initiation of CNS damage by this parasite. Costanzo and Perrino [30] observed that an olfactory nerve interruption caused an increase in the concentration of MMP-9 as well as upregulation of MMP-2 during recovery. The level of MMP-2 changed independently of MMP-9, probably due to the significant contribution of this metalloproteinase in axonal regeneration. Due to the fact that MMP activity during brain acanthamoebiasis is important for the migration of inflammatory cells and parasites as well as BBB integrity disorders, these enzymes might represent suitable therapeutic targets to prevent breaching of the brain–blood barrier in amoebic brain infection.
Interactions between MMP and TIMP can play a significant role in parasite pathogenesis based on the mechanisms of BBB substrate degradation and also function as effectors and regulators of the immune response [14]. TIMP-1 and TIMP-3 are capable of inhibiting various proteases and TNF-α [31]. TIMP upregulation in infected tissues does not compensate for the increased activity of proteolytic enzymes. Some researchers suggest that TIMP-1 may inhibit pathogen clearance during infection by limiting MMP-driven lymphocyte penetration into the CNS [14]. In animal experimental models of CNS this MMP inhibitor plays an important role in neuroprotection, neural plasticity and tissue repair [31]. MMP inhibitor production may increase to create a normal MMP/TIMP ratio and to regain BBB integrity by decreasing activated T cell migration [32].

This study demonstrated that TIMP-1 and TIMP-3 increased in the cerebral cortex in *Acanthamoeba* spp. infected immunocompetent mice at the beginning of infection. There was also a significant increase in TIMP-1 in the hippocampus of *Acanthamoeba* spp. infected immunocompetent mice compared to the cerebral cortex of *Acanthamoeba* spp. infected immunosuppressed mice. TIMP-3 levels in the cerebral cortex were significantly higher in immunocompetent than immunosuppressed *Acanthamoeba* spp. infected mice at 8 dpi. Moreover, infection with *Acanthamoeba* spp. in the hippocampus did not affect TIMP-3 in immunocompetent mice; a significant decrease in this inhibitor was observed only in immunosuppressed *Acanthamoeba* spp. infected mice at 16 dpi. The aforementioned variable activity of synthesized TIMP-1 and TIMP-3 inhibitors during brain acanthamoebiasis may be related to their different form of appearance in brain tissues. TIMP-1 is produced in a soluble form and can be degraded more quickly, while TIMP-3 is insoluble, bound to the intercellular matrix, and may decompose at a slower rate [33]. In addition, the decrease in the amount of TIMP may be due to increased MMP catalytic activity, and conversely, an increase in inhibitors may indicate a reduction in MMP activity. TIMP can act independently of MMP, involved in the regulation of cellular processes, including cell proliferation and apoptosis, and angiogenesis [34].

TIMP investigated in this study can participate in the regulation of inflammation and the cell cycle. TIMP-3 inhibits not only metalloproteinases but limits the activity of adamsin-like proteinases (ADAM), including ADAM-17—an enzyme converting TNF-α (TACE /ADAM 17) [35]. TNF-α can stimulate phagocytosis, proliferation of T and B lymphocytes, increase natural killer (NK) cell toxicity and stimulate the expression of MMP [36]. It is possible that an elevated concentration of TIMP-3 in the cerebral cortex and hippocampus of *Acanthamoeba* spp. infected immunocompetent mice may result from ongoing inflammation in the brain. Similarly, TIMP-1 and TIMP-3 mRNA expression was noted to be upregulated in *T. cruzi* infected heart tissue [26]. Some authors suggest that TIMP-1 and TIMP-3 may contribute to pathology in Post-kala-azar dermal leishmaniasis (PKDL) and may inhibit wound healing [37].

Due to the different roles of matrix metalloproteinases and their specific inhibitors, we analyzed the coefficients assessing the relationships between them. We found that MMP-9/TIMP-1 and MMP-2/TIMP-3 ratios were low and similar between the groups and brain structures, but increased in the hippocampus in *Acanthamoeba* spp. infected immunosuppressed mice (AS) at the beginning of infection. It is possible that in the AS group in the acute phase of the infection, the proteolytic activity of all components of the gelatinase inhibitor system was stimulated. Chronic immune activation and inflammation as well as immunodeficiency cause a homeostasis imbalance between MMP and TIMP in HIV positive patients, especially in those with neurocognitive disorders [15,38]. Lichtinghagen et al. [39] also observed the upregulation of MMP-9/TIMP-1 ratio in patients with multiple sclerosis.

4. Materials and Methods

4.1. Experimental Animal Model

The experimental course of acanthamoebiasis under study was described in detail in our earlier works [40,41]. The study had been approved by the Local Ethics Committee for Experiments on
Animals in Szczecin (No. 29/2015, dated 22 June 2015) and Poznań (No. 64/2016 dated 09 September 2016). It was conducted on 96 male Balb/c mice obtained from a licensed breeder (the Center of Experimental Medicine, Medical University in Białystok, Poland). At the start of the experiment, the age of the mice was 6–10 weeks. The animals had genetic and health certificates issued by a veterinarian. All animals were weighed, and their mean weight was 23 g. The animals were also evaluated by clinical observations, housed singly on a 12-h light/dark cycle, and fed Labofeed H feed (Morawski, Kcynia, Poland) and water ad libitum.

Inoculation of the mice was performed using *Acanthamoeba* spp. strain AM 22, isolated from a patient with acute myeloid leukemia (AML) and atypical pneumonia [42]. Parasites were grown in NN Agar covered with a suspension of deactivated *Escherichia coli* and incubated at 37 °C according to standard methods [43]. Strain AM 22 not only has pneumophilic properties, as we observed in our previous study [40], but also neurophilic effects, where numerous amoeba trophozoites were re-isolated from brain fragments from *Acanthamoeba* spp. infected immunocompetent and immunosuppressed mice.

For the in vivo studies animals were divided into 4 groups:

- immunocompetent control group uninfected mice (C, *n* = 18),
- immunocompetent *Acanthamoeba* spp. infected mice (A, *n* = 30),
- immunosuppressed *Acanthamoeba* spp. infected mice (AS, *n* = 30),
- immunosuppressed uninfected mice (CS, *n* = 18).

Animals were immunosuppressed by administering 0.22 mg (10 mg/kg) methylprednisolone sodium succinate (MPS, Solu-Medrol, Pfizer, Europe MA EEIG; cat. no.: W07908) in 0.1 mL of 0.9% saline intraperitoneally (i.p.) at −4, −3, −2, −1 and 0 days before inoculation with the amoeba. The model of immunosuppression in experimental acanthamoebiasis using MPS was based on literature data [44].

The mice from groups A and AS were inoculated intra-nasally with 3 µL of a suspension containing 10–20 thousand amoebae. Control animals (C and CS groups) were given the same volume of sterile solution (3 µL of 0.9% NaCl solution). Euthanasia of the *Acanthamoeba* spp. infected mice was conducted at 8, 16, and 24 days post infection (dpi), depending on the clinical signs and degree of infection, with a peritoneal overdose of sodium pentobarbital (Euthasol vet, FATRO) (2 mL/kg body weight) and subsequently necropsied. The virulence of the amoebae was determined by the degree of infection. Fragments (5 × 5 mm) of the brain were placed on NN agar and incubated at 41 °C to assess infection intensity. The cerebral cortex and hippocampus samples were fixed and stored in 4% buffered formalin solution (Avantor, Poland; cat. no.:432173111) for histological analyses and fixed in liquid nitrogen, and then stored at −80 °C biochemical analyses.

### 4.2. Determination of MMP-2, MMP-9, TIMP-3, TIMP-1 in the Brain

The collected brain structures (hippocampus, cerebral cortex) were homogenized in a hammer mill in liquid nitrogen, then lysis buffer was added to the tissue powder, followed by homogenization in a knife homogenizer. In order to perform the lysis of tissues and release relevant epitopes, the samples were subjected to five thaw-freeze cycles, then centrifuged (3000 G × 20 min × 4 °C) and the obtained supernatant used for further determinations.

The concentrations of MMP and TIMP were determined with commercially available quantitative ELISAs: MMP-2 (Mouse Matrix Metalloproteinase 2 ELISA Kit), MyBioSource (San Diego, CA, USA), cat. no.: MBS454416; MMP-9 (Mouse Matrix Metalloproteinase 9 ELISA Kit), MyBioSource, cat. no.: MBS355322; TIMP 3 (Mouse Tissue Inhibitors of Metalloproteinase 3 ELISA Kit) (San Diego, CA, USA) cat. no.: 454748; TIMP 1 (Mouse Tissue Inhibitors of Metalloproteinase 1 ELISA Kit) (San Diego, CA, USA) cat. no.: 2881293. The determinations were made according to the instructions provided by the manufacturers using an ASYS UVA 340 spectrophotometer.
4.3. Measurement of Total Protein Concentration by BCA

In order to standardize the obtained results, the samples were assayed for total protein level with bicinchoninic acid (BCA) using a commercially available kit (Pierce™ BCA Protein Assay Kit; (Thermofisher Waltham, MA, USA); cat. no.: 23225). The spectrometric measurement was carried out on an ASYS UVA 340 spectrophotometer.

4.4. Immunolocation of MMP-2, MMP-9, TIMP-1 and TIMP-3 by Immunohistochemical Methods

Paraffin-embedded sections (3–5 µm) of mouse brains were immunostained for the visualization of matrix metalloproteinases (MMP) and their inhibitors (TIMP) expression. Immunohistochemistry was performed using specific primary antibodies, monoclonal against MMP-2 (Thermofisher; Waltham, MA, USA) cat. no.: 436000; final dilution—1:100), MMP-9 (Thermofisher; Waltham, MA, USA) cat. no.: MA5-15886; final dilution—1:500), TIMP-1 (Thermofisher; Waltham, MA, USA) cat. no.: MA5-13688; final dilution—1:100) and polyclonal against TIMP-3 (Thermofisher; Waltham, MA, USA) cat. no.: PA5-26133; final dilution—1:25). First, the deparaffinized sections were microwave irradiated in citrate buffer (pH 6.0) to heat induce epitope retrieval. After slow cooling to room temperature, slides were washed in phosphate-buffered saline (PBS) solution twice for 5 min and then incubated with primary antibodies over the night in 4 °C. Following this, sections were stained using an avidin-biotin-peroxidase system with diaminobenzidine (DAKO LSAB+System-HRP; DakoCytomation, Glostrup, Denmark, cat. no.: K0679) as the chromogen, in conformity with the staining procedure instructions included. Sections were washed in distilled H₂O and counterstained with hematoxylin. For a negative control, specimens were processed in the absence of primary antibodies. Positive staining was defined microscopically (Leica DM5000 B, Wetzlar, Germany) by visual identification of brown pigmentation.

4.5. Statistical Analysis

The obtained results were analyzed statistically using Statistica 13.1 software. Arithmetical means and standard deviations (SD) were calculated for each of the studied parameters. In order to assess differences between the parameters studied, Kruskal-Wallis ANOVA followed by Mann–Whitney-U tests were used. Correlations between the parameters were examined with Spearman’s rank correlation coefficient (rₛ). Differences were considered statistically significant at p < 0.05.

5. Conclusions

Our results showed that Acanthamoeba spp. infection can change the levels of matrix metalloproteinases and tissue inhibitor of metalloproteinase in the central nervous system. The increase in the activity of matrix metalloproteinases during acanthamoebiasis may be primarily the result of inflammation process, probably an increased activity of proteolytic processes, but also (to a lesser extent) a defense mechanism preventing the processes of neurodegeneration. In addition, the level of both MMP and TIMP in brain tissue are up- or downregulated in Acanthamoeba spp. mice depending on the immunological status of the host and the brain structure studied. As MMP activity during brain acanthamoebiasis is important for the migration of inflammatory cells and parasites and BBB integrity disorders, these enzymes might represent suitable therapeutic targets to prevent the unsealing of brain–blood barrier in induced amoebic brain infection.
Author Contributions: Conceptualization, N.Ł.-A. and D.K.-B.; Methodology, N.Ł.-A., I.B.-B., K.K. and E.M.; Software, K.K., Validation, N.Ł.-A. and D.K.-B.; Formal analysis, N.Ł.-A., I.B.-B., I.G., A.K.-W., A.L., B.W., D.C., D.K.-B.; Writing-Original Draft Preparation, N.Ł.-A.; Writing-Review & Editing, N.Ł.-A. and D.K.-B.; Visualization, A.K.-W., B.W., N.Ł.-A.; Supervision, D.K.-B.; Project Administration and Funding, N.Ł.-A.

Funding: The Pomeranian Medical University in Szczecin provided financial support (FSN-431/08/17).

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

A immunocompetent Acanthamoeba spp. infected mice
ADAM adamalysin-like proteinases
AM 22 amoebic strain no. 22
AML acute myeloid leukemia
AS immunosuppressed Acanthamoeba spp. infected mice
BBB blood brain barrier
BCA bicinchoninic acid
C immunocompetent uninfected control group mice
cAMP cyclic adenosine monophosphate
CNS central nervous system
COX-2 cyclooxygenase-2
CS immunosuppressed uninfected mice
CSF cerebrospinal fluid
Dpi day post infection
GAE granulomatous amebic encephalitis
GCL granular cell layer
HIV human immunodeficiency virus
IHC Immunohistochemistry
IL-1 interleukin 1
IL-6 interleukin 6
IL-23 interleukin 23
LTP long term potentiation
MMPs matrix metalloproteinases
MMP-2 matrix metalloproteinase-2
MMP-9 matrix metalloproteinase-9
MPS methylprednisolone sodium succinate
NK natural killers
PBS phosphate-buffered saline
PDGF platelet-derived growth factor
PGE2 Prostaglandin E2
PKDL Post-kala-azar dermal leishmaniasis
PyrCL pyramidal cell layer
SD standard deviation
TACE/ADAM17ADAM metallopeptidase domain 17
TGF-β transforming growth factor—β
TIMP tissue inhibitor of metalloproteinase
TIMP-1 tissue inhibitor of metalloproteinase-1
TIMP-3 tissue inhibitor of metalloproteinase-3
TNF tumor necrosis factor
TNF-α tumor necrosis factor—α

References

1. Memari, F.; Niyayti, M.; Joneidi, Z. Pathogenic Acanthamoeba T4 genotype isolated from mucosal tissue of a patient with HIV infection: A Case Report. Iran. J. Parasitol. 2017, 12, 143–147.
8. Marciano-Cabral, F.; Cabral, G.

22. Yin, P.; Yang, L.; Zhou, H.Y.; Sun, R.P. Matrix metalloproteinase-9 may be a potential therapeutic target in disease. *Diagn. Pathol.* 2018, 13, 27. [CrossRef] [PubMed]

3. Ong, T.Y.Y.; Khan, N.A.; Siddiqui, R. Brain-eating amoebea: Predilection sites in the brain and disease outcome. *J. Clin. Microbiol.* 2017, 55, 1989–1997. [CrossRef]

4. Siddiqui, R.; Khan, N.A. Biology and pathogenesis of *Acanthamoeba*. *Parasit Vectors* 2012, 5, 6. [CrossRef] [PubMed]

5. Khan, N.A. *Acanthamoeba* and the blood-brain barrier: The breakthrough. *J. Med. Microbiol.* 2008, 57, 1051–1057. [CrossRef] [PubMed]

6. Lorenzo-Morales, J.; Khan, N.A.; Waløchnik, J. An update on *Acanthamoeba* keratitis: Diagnosis, pathogenesis and treatment. *Parasite* 2015, 22, 10. [CrossRef]

7. Elsheikha, H.M.; Khan, N.A. Protozoa traversal of the blood-brain barrier to invade the central nervous system. *FEMS Microbiol. Rev.* 2010, 34, 532–553. [CrossRef] [PubMed]

8. Marciano-Cabral, F.; Cabral, G. *Acanthamoeba* spp. as agents of disease in humans. *Clin. Microbiol. Rev.* 2003, 16, 273–307. [CrossRef]

9. Masocha, W.; Kristensson, K. Passage of parasites across the blood-brain barrier. *Virulence* 2012, 3, 202–212. [CrossRef]

10. Lakhan, S.E.; Kirchgessner, A.; Tepper, D.; Leonard, A. Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. *Front. Neurol.* 2013, 4, 32. [CrossRef]

11. Mukherjee, A.; Swarnakar, S. Implication of matrix metalloproteinases in regulating neuronal disorder. *Mol. Biol. Rep.* 2015, 42, 1–11. [CrossRef] [PubMed]

12. Rempe, R.G.; Hartz, A.M.; Bauer, B. Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers. *J. Cereb. Blood Flow Metab.* 2016, 36, 1481–1507. [CrossRef] [PubMed]

13. Ricci, S.; Grandgirard, D.; Wenzel, M.; Braccini, T.; Salvatore, P.; Oggoni, M.R.; Leib, S.L.; Koedel, U. Inhibition of matrix metalloproteinases attenuates brain damage in experimental meningococcal meningitis. *BMC Infect. Dis.* 2014, 14, 726. [CrossRef] [PubMed]

14. Bruschi, F.; Pinto, B. The significance of matrix metalloproteinases in parasitic infections involving the central nervous system. *Pathogens* 2013, 2, 105–129. [CrossRef] [PubMed]

15. Geurts, N.; Opdenakker, G.; Van den Steen, P.E. Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. *Pharmacol. Ther.* 2012, 133, 257–279. [CrossRef]

16. Lam, C.; Jamerson, M.; Cabral, G.; Carlesso, A.M.; Marciano-Cabral, F. Expression of matrix metalloproteinases in *Naegleria fowleri* and their role in invasion of the central nervous system. *Microbiology* 2017, 163, 1436–1444. [CrossRef] [PubMed]

17. Zhou, J.; Marten, N.W.; Bergmann, C.C.; Macklin, W.B.; Hinton, D.R.; Stohlman, S.A. Expression of matrix metalloproteinases and their tissue inhibitor during viral encephalitis. *J. Virol.* 2005, 79, 4764–4773. [CrossRef]

18. Shukla, V.; Shakya, A.K.; Shukla, M.; Kumari, N.; Krishnani, N.; Dhole, T.N.; Misra, U.K. Circulating levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases during Japanese encephalitis virus infection. *Virusdisease* 2016, 27, 63–76. [CrossRef]

19. Visvesvara, G.S. Infections with free-living amebae. *Handb. Clin. Neurol.* 2013, 114, 153–168. [CrossRef]

20. Doan, N.; Rozansky, G.; Nguyen, H.S.; Gelsomino, M.; Shabani, S.; Mueller, W.; Johnson, V. Granulomatous amebic encephalitis following hematopoietic stem cell transplantation. *Surg. Neurol. Int.* 2015, 6, S459–S462. [CrossRef]

21. Yu, C.F.; Chen, F.H.; Lu, M.H.; Hong, J.H.; Chiang, C.S. Dual roles of tumour cells-derived matrix metalloproteinase 2 on brain tumour growth and invasion. *Br. J. Cancer* 2017, 117, 1828–1836. [CrossRef] [PubMed]

22. Yin, P.; Yang, L.; Zhou, H.Y.; Sun, R.P. Matrix metalloproteinase-9 may be a potential therapeutic target in epilepsy. *Med. Hypotheses* 2011, 76, 184–186. [CrossRef]

23. Nagy, V.; Bozdagi, O.; Matynia, A.; Balcerzyk, M.; Okulski, P.; Dzwonek, J.; Costa, R.M.; Silva, A.J.; Kaczmarek, L.; Huntley, G.W. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. *J. Neurosci.* 2006, 26, 1923–1934. [CrossRef] [PubMed]

24. Jacintho, A.P.P.; Melo, G.D.; Machado, G.F.; Bertolo, P.H.L.; Moreira, P.R.R.; Momor, C.; Souza, T.A.; Vasconcelos, R.O. Expression of matrix metalloproteinase-2 and metalloproteinase-9 in the skin of dogs with visceral leishmaniasis. *Parasitol. Res.* 2018, 117, 1819–1827. [CrossRef] [PubMed]
25. Fares, R.C.; Gomes, J.A.; Garzoni, L.R.; Waghbi, M.C.; Saraiva, R.M.; Medeiros, N.I.; Oliveira-Prado, R.; Sangenis, L.H.; Chambela Mda, C.; de Araújo, F.F.; et al. Matrix metalloproteinases 2 and 9 are differentially expressed in patients with indeterminate and cardiac clinical forms of Chagas disease. * Infect. Immun. 2013, 81, 3600–3608. [CrossRef] [PubMed]

26. Gutierrez, F.R.; Lalu, M.M.; Marianos, F.S.; Milanzei, C.M.; Cena, J.; Gerlach, R.F.; Santos, J.E.; Torres-Dueñas, D.; Cunha, F.Q.; Schulz, R.; et al. Increased activities of cardiac matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental Trypanosoma cruzi infection. * J. Infect. Dis. 2008, 197, 1468–1476. [CrossRef] [PubMed]

27. Clark, R.T.; Nance, J.P.; Noor, S.; Wilson, E.H. T cell production of matrix metalloproteases and inhibition of parasite clearance by TIMP-1 during chronic toxoplasma infection in the brain. * ASN Neurol. 2010, 3, 1–12.

28. Rosenberg, G.A.; Dencoff, J.E.; Correa, N., Jr.; Reiners, M.; Ford, C.C. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury. * Neurology 1996, 46, 1626–1632. [CrossRef] [PubMed]

29. Green, J.A.; Tran, C.T.; Farrar, J.J.; Nguyen, M.T.; Nguyen, P.H.; Dinh, S.X.; Ho, N.D.; Ly, C.V.; Tran, H.T.; Friedland, J.S.; et al. Dexamethasone, cerebrospinal fluid matrix metalloproteinase concentrations and clinical outcomes in tuberculous meningitis. * PloS ONE 2009, 4, e7277. [CrossRef]

30. Costanzo, R.M.; Perrino, L.A. Peak in matrix metalloproteinases-2 levels observed during recovery from olfactory nerve injury. * Neuroreport 2008, 19, 327–331. [CrossRef] [PubMed]

31. Moore, C.S.; Crocker, S.J. An alternate perspective on the roles of TIMPs and MMPs in pathology. * Am. J. Pathol. 2012, 180, 12–16. [CrossRef] [PubMed]

32. Acar, B.A.; Öztekin, Z.N.; Öztekin, M.F.; Acar, T. Serum MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in experimental Trypanosoma rhodesiense infection. * Folia Biol. 2018, 65, 161–172. [CrossRef]

33. Yu, W.H.; Yu, S.; Meng, Q.; Brew, K.; Woessner, J.F.J. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. * J. Biol. Chem. 2000, 275, 31226–31232. [CrossRef] [PubMed]

34. Baker, A.H.; Edwards, D.R.; Murphy, G. Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. * J. Cell Sci. 2002, 115, 3719–3727. [CrossRef] [PubMed]

35. Amour, A.; Slocombe, P.M.; Webster, A.; Butler, M.; Knight, C.G.; Smith, B.J.; Stephens, P.E.; Shelley, C.; Hutton, M.; Knäuper, V.; et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. * FEBS Lett. 1998, 435, 39–44. [CrossRef]

36. Tsai, C.L.; Chen, W.C.; Hsieh, H.L.; Chi, P.L.; Hsiao, L.D.; Yang, C.M. TNF-α induces matrix metalloproteinase-9-dependent soluble intercellular adhesion molecule-1 release via TRAF2-mediated MAPKs and NF-κB activation in osteoblast-like MC3T3-E1 cells. * J. Biomed. Sci. 2014, 21, 12. [CrossRef] [PubMed]

37. Ansari, N.A.; Katara, G.K.; Ramesh, V.; Salotra, P. Evidence for involvement of TNFR1 and TIMPs in the pathogenesis of post-kala-azar dermal leishmaniasis. * Clin. Exp. Immunol. 2008, 154, 391–398. [CrossRef] [PubMed]

38. Xing, Y.; Shepherd, N.; Lan, J.; Li, W.; Rane, S.; Gupta, S.K.; Zhang, S.; Deng, J.; Yu, Q. MMPs/TIMPs imbalances in the peripheral blood and cerebrospinal fluid are associated with the pathogenesis of HIV-1-associated neurocognitive disorders. * Brain Behav. Immun. 2017, 65, 161–172. [CrossRef]

39. Lichtinghagen, R.; Seifert, T.; Kracke, A.; Marckmann, S.; Wurster, U.; Heidenreich, F. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. * J. Neuroimmunol. 1999, 99, 19–26. [CrossRef]

40. Łanocha-Arendarczyk, N.; Baranowska-Bosiacka, I.; Kot, K.; Gutowska, I.; Kolas-Wołosiuk, A.; Chlubek, D.; Kosik-Bogacka, D. Expression and activity of COX-1 and COX-2 in *Acanthamoeba* sp. infected lungs according to the host immunological status. * Int. J. Mol. Sci. 2018, 19, 121. [CrossRef] [PubMed]

41. Łanocha-Arendarczyk, N.; Baranowska-Bosiacka, I.; Kot, K.; Pilarczyk, B.; Tomza-Marciniak, A.; Kabat-Koperska, J.; Kosik-Bogacka, D. Biochemical profile, liver and kidney selenium (Se) status during infection. * Acta Protozool. 2009, 48, 271–279.
43. Culbertson, C.G.; Ensminger, P.W.; Overton, W.M. The isolation of additional strains of pathogenic Hartmanella sp. (Acanthamoeba): Proposed culture method for application to biological material. *Am. J. Clin. Pathol.* **1965**, *43*, 383–387. [CrossRef] [PubMed]

44. Markowitz, S.M.; Sobieski, T.; Martinez, A.J.; Duma, R.J. Experimental Acanthamoeba infections in mice pretreated with methylprednisolone or tetracycline. *Am. J. Pathol.* **1978**, *92*, 733–744.

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).